Chronic myeloid leukaemia (supportive care)
Also known as: Chronic myeloid leukaemia, Chronic myelogenous leukaemia, CML, BCR::ABL1-positive chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by BCR::ABL1 tyrosine kinase activity. Primary management involves haematologist-led therapy—typically tyrosine kinase inhibitors (TKIs)—and rigorous molecular monitoring. Supportive Traditional Chinese Medicine (TCM) may be utilised as an adjunct for managing secondary symptoms such as fatigue, gastrointestinal dysfunction, insomnia, or psychological distress; however, it does not constitute a primary treatment for leukaemia and has no demonstrated impact on molecular response. Extant research offers no CML-specific evidence regarding the efficacy of acupuncture or herbal medicine; findings in broader oncology reviews remain heterogeneous and inconclusive. The TCM patterns detailed herein function as frameworks for symptomatic management rather than markers of oncological staging. Prior to adjunctive intervention, new clinical symptoms must be evaluated to exclude treatment toxicity, infection, cytopenia, or disease progression. Any herbal medicine use requires formal oncology and pharmacist review to screen for potential drug-herb interactions.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain strict adherence to all prescribed CML pharmacotherapy and molecular-monitoring protocols; report adverse effects to the treating specialist and avoid self-directed dose modifications.
- •Maintain a symptom log documenting fatigue, sleep quality, bowel function, and dyspnoea to identify potential correlations with medication timing or dosage.
- •Prioritise pacing and graded activity interspersed with scheduled rest periods, ensuring physical exertion aligns with current haematological status and oncological advice.
- •Ensure consistent nutritional intake and stringent food hygiene; consult an oncology pharmacist or dietitian before introducing herbal medicines, supplements, or significant dietary alterations.
Cautions & Contraindications
- •Defer needling with fever, active infection, significant bleeding, clinically important thrombocytopenia or neutropenia until the oncology team confirms suitability. Use current blood results and local oncology protocols rather than universal numerical cut-offs. These are precautionary clinical safeguards, not thresholds established by the supplied review.[]
- •Do not begin herbal formulas without product-level interaction review, particularly with TKIs, anticoagulants or abnormal liver tests. The supplied CAM review supports case-by-case assessment but does not establish the safety of these combinations.[]
- •Do not treat new breathlessness as a traditional fluid pattern or use adjunctive care to delay investigation. Suspected dasatinib-associated effusion requires medical management; any medicine interruption is the prescriber's decision.[]
When to reassess or seek care again
If oncology-approved adjunctive treatment is undertaken, review after 2–4 weeks using baseline and follow-up fatigue and distress scores from 0–10, sleep duration, bowel frequency and appetite. Stop or modify care if symptoms worsen, adverse effects occur or there is no meaningful patient-reported benefit. New breathlessness, fever or bleeding requires immediate medical escalation rather than waiting for review. Molecular response and blood counts remain the haematology team's monitoring outcomes, not evidence of adjunctive efficacy.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Respirology case reports · 2026
- Frontiers in immunology · 2025
- Briefings in bioinformatics · 2026
- Healthcare (Basel, Switzerland) · 2024
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
